The short version of thymosin beta-4 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-02-21 and is reviewed periodically as new material appears.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
TB-500 is a research peptide whose sequence matches residues 17 to 23 of thymosin beta-4, a 43-residue protein present in most mammalian cells. The chain is seven amino acids long, written as LKKTETQ, and is normally supplied with an acetyl group on the N-terminus. Suppliers list it as a lyophilised powder under the code name TB-500, and the same sequence appears elsewhere in catalogues as the thymosin beta-4 actin-binding fragment. The label is commercial rather than systematic, so no single authority fixes exactly what TB-500 denotes.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
MRI for imaging anatomical structures or blood flow do not require contrast agents since the varying properties of the tissues or blood provide natural contrasts. However, for more specific types of imaging, exogenous contrast agents may be given intravenously, orally, or intra-articularly. Most contrast agents are either paramagnetic (e.g.: gadolinium, manganese, europium), and are used to shorten T1 in the tissue they accumulate in, or super-paramagnetic (SPIONs), and are used to shorten T2 and T2* in healthy tissue reducing its signal intensity (negative contrast agents). The most commonly used intravenous contrast agents are based on chelates of gadolinium, which is highly paramagnetic. In general, these agents have proved safer than the iodinated contrast agents used in X-ray radiography or CT. Anaphylactoid reactions are rare, occurring in approx. 0.03–0.1%. Of particular interest is the lower incidence of nephrotoxicity, compared with iodinated agents, when given at usual doses—this has made contrast-enhanced MRI scanning an option for patients with renal impairment, who would otherwise not be able to undergo contrast-enhanced CT. Gadolinium-based contrast reagents are typically octadentate complexes of gadolinium(III). The complex is very stable (log K > 20) so that, in use, the concentration of the un-complexed Gd3+ ions should be below the toxicity limit.
Chemerin peptides are short peptides (on the order of 9 amino acids) that are produced from the carboxyl terminus of the chemokine chemerin. Chemerin is an chemotactic adipokine; essentially a signalling protein that is involved in adipogenesis and immune response. Chemerin peptides display the same activities as chemerin, although at higher efficacy and potency.
On his retirement, Mahathir was named a Grand Commander of the Order of the Defender of the Realm, the highest honour in Malaysia, allowing him to adopt the title of "Tun". Under Mahathir's leadership, Malaysia was transformed into an industrialising nation. He pledged to leave politics "completely", rejecting an emeritus role in Abdullah's cabinet. Abdullah immediately made his mark as a quieter and less adversarial premier. With stronger religious credentials than Mahathir, he beat back PAS's surge in the 1999 election and lead the Barisan Nasional in the 2004 election to its biggest win ever, taking 199 of 219 parliamentary seats. On 23 October, Mingguan Malaysia, a Sunday edition of Utusan Malaysia, published an exclusive interview with Mahathir, marking his first since retiring as prime minister. After retiring, Mahathir maintained a busy schedule, engaging in various activities and speaking engagements both locally and internationally. In 2005, Russian president Vladimir Putin visited him at his private residence, where they held a four-hour meeting discussing Malaysia's economic transformation and development strategies. He emphasized the importance of staying active, stating, "Never retire. You have to work. When you work, it will keep you alive." His office at the Perdana Leadership Foundation and residence at the Mines Resort City, as well as expenses for meal allowances, escorts, bodyguards, a medical officer, and a special assistant during overseas trips, are funded by the government under the Member of Parliament (Remuneration) Act 1980 (Act 237).
=== THC vis-à-vis CBD === During the selective breeding process for medical marijuana, THC:CBD ratios are accounted for and accommodated to the needs of the client's preference/illness. Due to the large genetic diversity and different geographical climates and environments, a wide range of strains and properties exist. THC is associated with the psychoactive high, while CBD is not psychoactive and is purported to have medicinal properties. However, conversion of CBD to THC can occur when CBD is heated to temperatures between 250–300 °C, potentially leading to its partial transformation into THC.
Sources: en.wikipedia.org
June 19, 1987: Law concerning the duration and organization of working time. July 22, 1987: Law on the exercise of parental authority. July 18, 1988: Creation of the Secretary of State for Women's Rights, assigned to Michèle André. December 28, 1988: Order concerning the possession, distribution, dispensing, and administration of the drug Mifepristone 200 mg tablets. May 16, 1989: Decree removing the managerial and technical staff of the prison administration's external services from the list of positions for which separate recruitment could be planned for men and women. July 10, 1989: Framework law on education. July 10, 1989: Law on the prevention of child abuse and the protection of children. February 20, 1990: Order amending the order of November 3, 1988, concerning the prices of care and hospitalization related to voluntary termination of pregnancy. July 6, 1990: Law amending the Social Security Code and relating to family benefits and employment assistance for the care of young children. September 5, 1990: Marital rape is recognized for the first time by the Court of Cassation. December 21, 1990: The Council of State validates the conformity of the 1975 Veil Law with the European Convention on Human Rights. January 18, 1991: Law containing provisions relating to public health and social insurance. January 31, 1991: Decree concerning the responsibilities of the Secretary of State for Women's Rights and Daily Life, delegated by the Minister of Labour, Employment, and Vocational Training. May 1991: Édith Cresson becomes the first female Prime Minister of France.
where : x, y, and z are the stoichiometric coefficients of each species. M stands for metal / metal ion, the L for Lewis bases, and finally Z for complex ions. Formation constants vary widely. Large values indicate that the metal has high affinity for the ligand, provided the system is at equilibrium. Sometimes the stability constant will be in a different form known as the constant of destability. This constant is expressed as the inverse of the constant of formation and is denoted as Kd = 1/Kf . This constant represents the reverse reaction for the decomposition of a complex ion into its individual metal and ligand components. When comparing the values for Kd, the larger the value, the more unstable the complex ion is. As a result of these complex ions forming in solutions they also can play a key role in solubility of other compounds. When a complex ion is formed it can alter the concentrations of its components in the solution. For example:
Dezocine acts as an opioid receptor receptor modulator. It is specifically a mixed agonist–antagonist or partial agonist of the μ- and κ-opioid receptors. It is a biased agonist of the μ-opioid receptor and activates G protein signaling but not the β-arrestin pathway. This may account for some of dezocine's unique and atypical pharmacological properties. The binding affinity of dezocine varies depending on the opioid receptor, with the drug having the highest affinity for the μ-opioid receptor, intermediate affinity for the κ-opioid receptor, and the lowest affinity for the δ-opioid receptor. In addition to its opioid activity, dezocine has been found to act as a serotonin–norepinephrine reuptake inhibitor (SNRI), with pIC50 values of 5.86 for the serotonin transporter (SERT) and 5.68 for the norepinephrine transporter (NET). These actions theoretically might contribute to its analgesic efficacy. Dezocine is five times as potent as pethidine and one-fifth as potent as butorphanol as an analgesic. Due to its partial agonist nature at the μ-opioid receptor, dezocine has significantly reduced side effects relative to opioid analgesics acting as full agonists of the receptor such as morphine. Moreover, dezocine is not a controlled substance and there are no reports of addiction related to its use, indicating that, unlike virtually all other clinically employed μ-opioid receptor agonists (including weak partial agonists like buprenorphine), and for reasons that are not fully clear, it is apparently non-addictive.
=== Video games === Half-Life (1998) Half-Life 2 (2004) Half-Life 2: Episode One (2006) Half-Life 2: Episode Two (2007) Portal (2007) Counter-Strike: Global Offensive (additional music, 2015) Vanishing Realms: Rite of Steel (2016-2019)
(CH2CH2)O + RONa → RO–CH2CH2–O−Na+ RO–CH2CH2–O−Na+ + n (CH2CH2)O → RO–(CH2CH2–O)n–CH2CH2–O−Na+ RO–(CH2CH2–O)n–CH2CH2–O−Na+ → RO–(CH2CH2–O)n–CH=CH2 + NaOH RO–(CH2CH2–O)n–CH2CH2–O−Na+ + H2O → RO–(CH2CH2–O)(n+1)OH + NaOH
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
Sealed, desiccated and protected from light, at -20 °C or lower for long-term storage. Short-term storage at refrigerator temperature is common in working laboratories.